Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.33 |
| ▸ | ACE | P12821 | 5/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955491 | 0.78 | LTA4H (0.33) | ALDH1A1HSD17B10ACE | |
| SCHEMBL4954448 | 0.75 | ALDH1A1 (0.35) | ALDH1A1HSD17B10 | |
| SCHEMBL4955982 | 0.71 | BBOX1 (0.35) | POLBL3MBTL1 | |
| SCHEMBL27973416 | 0.71 | POLB (0.34) | ALDH1A1HSD17B10POLBL3MBTL1 | |
| SCHEMBL29588126 | 0.70 | HTT (0.37) | ALDH1A1HSD17B10POLB | |
| SCHEMBL15392569 | 0.70 | HPGD (0.37) | ALDH1A1HSD17B10CHRM2CHRM4CHRM5 | |
| SCHEMBL2732689 | 0.69 | HPGD (0.38) | ALDH1A1HSD17B10 | |
| SCHEMBL27689582 | 0.67 | HTT (0.43) | ALDH1A1HSD17B10POLBL3MBTL1 | |
| SCHEMBL3798847 | 0.67 | EPHX2 (0.36) | ALDH1A1L3MBTL1 | |
| SCHEMBL15414815 | 0.66 | RIPK1 (0.36) | ALDH1A1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | ALDH1A1 3352/4885HSD17B10 2758/4885CHRM2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.